Yakult trial takes 4SC's resminostat into NSCLC
This article was originally published in Scrip
Following the news in June that 4SC was cutting around 15% of its staff to reduce costs and focus resources on its lead development project resminostat (scripintelligence.com, 20 June 2013), it must come as some relief to the German biotech firm that the anticancer is now moving forward in a new indication in Japan.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.